Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IAGO for High-Risk MDS or AML
NCT00077116Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Nov 2003
- Primary completion
- Nov 2006
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of gemtuzumab ozogamicin in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), sponsored by European Organisation for Research and Treatment of Cancer. Started Nov 2003; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
myelodysplastic syndromes (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00077116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00077116.